Ensoma Secures $53 Million to Advance First-in-Class Gene Therapy for X-Linked Chronic Granulomatous Disease
核心洞察
Ensoma (搜索) raised $53 million from top-tier investors including Gilead to support its Phase 1/2 clinical trial of EN-374, a first-in-class in vivo hematopoietic stem cell therapy for X-linked chronic granulomatous disease (搜索).
The company's EN-374 therapy uses virus-like particles to deliver genetic payloads that engineer stem cells to restore NADPH oxidase (搜索) function in neutrophils, addressing a critical immune deficiency.
X-linked CGD affects approximately 1 in 100,000-200,000 live births with a median life expectancy of 45 years, representing a significant unmet medical need with limited current treatment options.
Ensoma (搜索) announced the closing of a $53 million financing round to support key clinical milestones for its lead candidate EN-374, a first-in-class in vivo hematopoietic stem cell therapy for X-linked chronic granulomatous disease (搜索) (X-CGD). The Boston-based company has opened patient enrollment for its Phase 1/2 clinical trial, marking its transition to a clinical-stage biotechnology company.
The financing was led by existing investors including Gilead Sciences, which appointed an executive to Ensoma (搜索)'s board of directors as part of its investment. Other participants include 5AM Ventures, Catalio Capital Management, Cormorant Asset Management, Delos Capital, F-Prime, the Gates Foundation, Hanwha Impact Partners, Mirae Asset Financial Group, Qatar Investment Authority, RTW, Solasta Ventures, SymBiosis, and Viking Global Investors.
Novel Approach to Genetic Immune Deficiency
EN-374 represents a breakthrough approach to treating X-CGD through in vivo hematopoietic stem cell engineering. The therapy employs virus-like particles (VLPs) to deliver genetic payloads that engineer HSCs with the goal of driving sustained expression of a CYBB (搜索) transgene in neutrophils. This mechanism aims to restore function of the infection-fighting NADPH oxidase (搜索) enzyme complex, which is critical for immune defense in patients with CYBB gene mutations.
In preclinical animal studies, EN-374 demonstrated the restoration of CYBB (搜索) protein expression and NADPH oxidase (搜索) activity in circulating neutrophils. The company is currently recruiting participants for a Phase 1/2 open-label, single-ascending-dose study designed to evaluate the safety and potential efficacy of EN-374 in patients with X-CGD.
Addressing Significant Unmet Medical Need
Chronic granulomatous disease (搜索) is a rare, severe genetic disorder affecting approximately 1 in 100,000-200,000 live births. The median life expectancy for individuals with the condition is around 45 years. X-linked CGD, the most common form comprising 60-70% of cases, is caused by CYBB (搜索) gene mutations that prevent neutrophils from effectively fighting infections.
Patients with CGD are vulnerable to recurrent, severe bacterial and fungal infections, often leading to chronic and life-threatening dysregulated inflammation and serious complications. Current treatments, including antibiotics, antifungals, interferon gamma, and allogeneic stem cell transplantation, offer limited benefit and come with significant treatment burdens.
Platform Technology with Broader Applications
"The $53 million financing reflects growing interest in our platform's potential to address serious diseases through one-time, outpatient treatments," said Jim Burns, CEO of Ensoma (搜索). "This is a defining moment for Ensoma as we are now a clinical-stage company and recruiting participants for our Phase 1/2 trial for EN-374 to treat X-linked CGD."
Ensoma (搜索)'s platform combines proprietary base editing or high-efficiency gene integration systems with high-capacity virus-like particles. The delivery system is based on VLPs that preferentially bind to HSCs, delivering DNA to the nucleus. With a 35-kilobase cargo capacity, these VLPs can carry sophisticated genomic engineering tools capable of introducing changes from single base edits to large multi-gene insertions, along with control elements for HSC-lineage cell specific expression.
Beyond X-CGD, the company is expanding its platform's potential global impact in immuno-oncology and sickle cell disease (搜索), positioning Ensoma (搜索) to address multiple therapeutic areas with its in vivo engineered cell therapy approach.
Clinical Trial Details
The Phase 1/2 trial for EN-374 is registered under NCT06876363 on ClinicalTrials.gov. The open-label, single-ascending-dose study will evaluate both safety and potential efficacy endpoints in patients with X-CGD. Burns emphasized that the company has established a strong manufacturing foundation and is positioned to begin generating meaningful human data for its first-in-class therapy.
The financing will support key clinical readouts from the EN-374 trial while enabling continued development of Ensoma (搜索)'s broader pipeline of in vivo hematopoietic stem cell engineering therapies.